PMID: Summary Keywords autoimmune diseases, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, incretin-based therapy, psoriasis, real-world evidence Citation Chiang Y-L, Li T-H, Fang Y-W, Liu Y-F, Wu J and Tsai M-H (2026) Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation
Choose Injectable Delivery When: Maximum bioavailability and systemic distribution are required Your peptide has a molecular weight exceeding 6,000 Da Precise dosing and reproducible pharmacokinetics are necessary Youre using peptides for bodybuilding or muscle growth The peptide lacks CNS targets Choose Nasal Delivery When: Direct CNS delivery and blood-brain barrier bypass are therapeutic objectives Your peptide is small (under 6,000 Da) and shows adequate nasal bioavailability Rapid onset of action (minutes) is clinically valuable Patient compliance and comfort are primary concerns Youre using neurological peptides like Semax or Selank The FDA has approved several intranasal peptide formulations, including ZAVZPRET for acute migraine treatment, validating this delivery route as pharmaceutically viable
Check in with your clinician if side effects feel impactful and disruptive
1 wellness partner of 2025, awarding the brand with a Partnership Award for the Wellness Tour and its launch activations
Efectos gastrointestinales: Las nuseas son el efecto secundario ms comn, afectando aproximadamente al 20-40% de los pacientes segn los estudios clnicos, con mayor incidencia durante la titulacin inicial y los aumentos de dosis
If you're curious about GLP-1s, we'll give you a clear picture of benefits and trade-offs and help you build a plan that prioritizes safety and resultsstarting with what works best today
